刚刚过去的这个国庆中秋假期 不少人在阖家欢聚、好友聚餐后 开始被腹胀、乏力、体重悄然上涨的 "节后综合征"缠上 对此记者走访了多学科专家 希望能为大家排忧解难 湖南省人民医院 临床营养科主任营养师蔡华建议 首先，需要理性对待身体变化 面对节后的体重上升 有人急于求成"极端节食" 却不知这会打乱身体代谢规律 不仅容易导致低血糖、乏力 还会触发后续的报复性进食 陷入"节食-暴食-体重反弹"的 恶性循环 其次，节后饮食的核心原则是 "清淡、均衡、适量" 重点抓好控盐、控油、控糖 "三控"工作 就能让超负荷的消化系统 快速恢复常态 蔡华说，成人每日食盐摄入量 建议控制在5克以内 （约一个标准啤酒瓶盖的量） ↓下面是医生建议的日常控盐tips 控油是减重的关键环节 油脂热量高 是导致体重飙升的重要因素 成人每日烹调用油 应严格控制在25-30克（约2-3汤匙） ↓下面是医生建议的日常控油tips 湖南省人民医院内分泌科主任张弛建议 控制体重首先要做好控糖工作 稳定血糖，才能避免脂肪堆积 成人每日添加糖摄入量 最好控制在25克以下 ↓下面是医生建议的日常控糖tips 充足饮水也至关重要 成年女性每日至少饮用1.5升水 成 ...

以下文章来源于肥胖世界ObesityWorld ，作者肥胖世界 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 许多人追求快速瘦身效果，采取激进饮食策略：完全避开碳水、仅食用水煮蔬菜，或每日进行高强度有氧训练。表面上短期内效果显著，实则 暗藏严重隐患。持续过度限食会触发身体"节能模式"，自动调低代谢水平，如同空调被设定更低温度，日常能量消耗逐渐减少。一旦饮食恢 复，身体会如"惊弓之鸟"般，竭力储存能量，导致体重迅速反弹。 体重计上数字的下滑并非意味着脂肪真正减少。实际上，短期内消失的往往是水分，甚至是宝贵的肌肉组织。肌肉作为人体能量代谢的"核心 引擎"，一旦流失会导致基础代谢率降低，即使静止状态下，机体消耗能量也会显著减少。这种情况下，恢复常规饮食后，身体更易储存热 量，体重随之迅速攀升。 特别在极限饮食控制或过量运动情境中，若蛋白质摄入不足，肌肉流失现象尤为明显。长期如此，不仅减脂效率持续下降，还会步入"愈减愈 难、愈减愈易反弹"的恶性循环。 而盲目大量运动若缺乏科 ...

"朋友们，我连着喝了一周'无糖'奶茶，竟然胖了两斤。" "低脂"不代表低能量 脂肪的能量密度比碳水化合物和蛋白质高，但这并不意味着低脂食品就一定是低能量的。 "你醒醒啊！你喝的'无糖'奶茶里可能加了植脂末，能量比糖还高呢！" "啊？原来都是套路！想要减重怎么这么难？" 减重路上，朋友们的疑问特别多，节食太痛苦，运动难坚持，怎么办呢？别担心，医学营养减重有妙 招。 "健康食品" 可能并不健康 为了弥补去除脂肪后的口感损失，很多低脂食品都加入了更多的糖或者淀粉。例如，一些低脂酸奶、低 脂饼干等，含糖量往往较高，能量并不低。长期食用这类高糖的低脂食品，不仅不利于减重，还可能导 致血糖水平剧烈波动，增加脂肪堆积的风险。 "无糖"不一定不升血糖 有些食品标注了"0蔗糖"，但这并不代表该食品不含葡萄糖、麦芽糖、果糖等其他糖分。而且，"无 糖"食品虽然没有添加单糖和双糖，但有些会添加代糖、非糖类甜味剂及抗性糊精、聚葡萄糖等膳食纤 维，过量食用含代糖的食品，可能会影响肠道菌群，进而影响身体健康。 此外，一些所谓的"无糖"食品即便符合国家规定的"0添加糖"标准，但其原料本身可能富含糖分，如果 汁、乳制品、糕点等淀粉制品，过量食 ...

Core Viewpoint - The article emphasizes that effective weight loss requires a scientific approach rather than extreme dieting or excessive exercise, highlighting the importance of maintaining muscle mass and a balanced lifestyle to avoid rebound weight gain [6][10][15]. Group 1: Weight Loss Challenges - Many individuals experience weight fluctuations, often losing weight only to regain it quickly, which may be due to ineffective weight loss methods [6]. - The concept of "false weight" is introduced, indicating that weight loss on the scale may not reflect actual fat loss, as it could be water or muscle loss instead [7]. - Extreme dieting and excessive exercise can lead to muscle loss and a decrease in metabolic rate, making it harder to maintain weight loss and leading to a cycle of rebound weight gain [8][10]. Group 2: Scientific Weight Loss Strategies - A healthy weight loss rate is suggested to be about 0.5% to 1% of body weight per week, equating to approximately four to ten pounds per month [12]. - Combining diet and exercise is crucial; a balanced intake of quality proteins and regular physical activity, including both aerobic and strength training, is recommended to preserve muscle and enhance metabolism [12]. - After achieving weight loss goals, a consolidation period of 1 to 3 months is necessary to maintain new weight levels by continuing healthy habits [12]. Group 3: GLP-1 Weight Loss Method - The GLP-1 weight loss method is introduced as a new approach for those struggling with weight loss or experiencing rebound effects [13]. - GLP-1, a hormone secreted by the intestines, helps control appetite and prolongs gastric emptying, leading to reduced caloric intake [13][14]. - Compared to traditional dieting and exercise, GLP-1 has the advantage of promoting fat loss rather than just water or muscle loss, resulting in more sustainable weight loss [14]. - It is emphasized that GLP-1 usage should be under medical supervision, and it should be combined with healthy lifestyle changes for long-term effectiveness [14].

Core Viewpoint - The frozen dough market is experiencing a recovery trend in 2025, driven by an expanding consumer base and a 2.6% year-on-year sales growth, with a 2.4 percentage point increase in penetration rate [1] Group 1: Market Trends - The fast-paced lifestyle has led consumers to demand higher standards for frozen dough products, focusing on health, taste, and adaptability to different meal scenarios [4] - The "scientific weight loss" strategy is promoting a refined and focused approach to health concepts in frozen dough products, with an increasing emphasis on natural ingredients like whole grains and buckwheat [5][6] - The market for frozen snacks is a key growth driver, with a 3.2 percentage point increase in penetration rate, particularly in the "baking + freezing" crossover products like frozen pizzas and egg tarts [8] Group 2: Product Innovation - Brands are upgrading ingredients to enhance taste and nutritional value, such as replacing water with fresh milk in buns and using high-quality fats in pancakes [6] - Functional frozen dough products are emerging to meet specific consumer needs, such as low-sugar dumplings for older adults and low-sodium options for health-conscious consumers [6] Group 3: Consumer Behavior - Breakfast is identified as the primary consumption scenario for frozen products, accounting for over 43% of total spending on frozen items, highlighting the importance of energy and taste preferences during this meal [12] - The popularity of kitchen appliances like air fryers and microwaves is expanding the usage scenarios for frozen dough products, allowing for creative cooking methods that enhance family interaction [12] Group 4: Future Outlook - The recovery of the frozen dough market reflects evolving consumer demands and industry efforts in health upgrades, product innovation, and scenario matching, indicating a competitive yet opportunity-rich future [15]

Group 1 - The Fourth China Obesity Conference (COC2025) emphasizes the need for national awareness and standardized treatment for obesity, integrating multiple disciplines to explore best practices and latest research in obesity prevention and treatment [1] - The World Obesity Federation predicts that by 2030, over 50% of adults globally will be overweight or obese, with China expected to have the highest absolute number of overweight and obese individuals, posing significant public health challenges [1] - The National Health Commission released the "Obesity Diagnosis and Treatment Guidelines (2024 Edition)," which outlines a multidisciplinary treatment approach and emphasizes the need for individualized plans for patients based on the severity of obesity [2] Group 2 - The establishment of a graded diagnosis and treatment system for obesity is urgently needed, focusing on high-risk groups such as those with severe obesity [2] - The conference highlights the importance of integrating obesity management into clinical medicine as an independent discipline, focusing on research, standardized treatment, and lifelong weight management [2] - New drugs and technologies are emerging, providing new opportunities for obesity treatment, with Chinese scholars exploring innovative treatment models combining surgery and medication [3] Group 3 - The conference aims to break down disciplinary barriers and discuss cutting-edge issues in weight management, including drug development and the application of artificial intelligence [3] - The Chinese Obesity Alliance calls for healthcare institutions and professionals to engage in scientific and standardized weight management education, promoting a shift from a disease-centered approach to a health-centered approach [3] - The "Scientific Weight Loss: Blue Dragonfly Action" initiative was launched to promote healthy living, attracting over 200 participants to engage in a health run [4]

Group 1 - JD Health participated in the "Weight Management Industry Conference 2025" and shared its advantages in providing convenient and scientific weight management solutions through an online and offline retail supply chain and professional healthcare services [1] - The new generation weight loss drug "Masitide" (brand name: Xin'ermei) from Innovent Biologics was launched on JD Health's platform shortly after its approval, highlighting the collaboration between the two companies to promote health knowledge related to weight loss and diabetes [1] - From July 4 to August 4, the search volume for "Xin'ermei" on JD's platform exceeded one million, with over 30,000 users served in the first month, indicating a strong demand for scientific weight loss medications [1] Group 2 - JD Health has established a nationwide network of 33 pharmaceutical warehouses, ensuring that 90% of orders can be delivered on the same day or the next day in nearly 400 cities [2] - For GLP-1 drugs requiring 2-8°C cold chain delivery, JD Health offers same-city cold chain delivery within 2 hours, and the "JD Buy Medicine Fast Delivery" service can deliver in as little as 9 minutes [2] - JD Health plans to deepen its collaboration with Innovent Biologics to leverage its comprehensive health weight management system, aiming to make innovative drugs accessible to more people in need [2]

Group 1 - JD Health participated in the "Weight Management Industry Conference 2025" and shared its advantages in providing convenient and scientific weight management solutions through an integrated online and offline retail supply chain and professional healthcare services [1] - The new generation weight loss drug "Masitide" (brand name: Xin Er Mei®) from Innovent Biologics was launched on JD Health's platform shortly after its approval, highlighting the collaboration to promote health knowledge related to weight loss and diabetes [3] - From July 4 to August 4, the search volume for "Xin Er Mei" on JD's platform exceeded one million, with over 30,000 users served in the first month, indicating a strong demand for scientific weight loss medications [3] Group 2 - JD Health's nationwide layout of 33 pharmaceutical warehouses ensures that 90% of orders can be delivered on the same or next day, with cold chain delivery for GLP-1 drugs available within 2 hours [3] - The "JD Buy Medicine Fast Delivery" service can deliver medications in as little as 9 minutes, allowing users to access necessary drugs promptly [3] - JD Health plans to deepen its collaboration with Innovent Biologics to enhance its comprehensive health weight management system, aiming to benefit more individuals in need of innovative medications [4]

Core Insights - Obesity has become a significant public health challenge, and there is a growing need for scientific weight loss methods and medication [4][36] - The "China Public Health Weight Loss Cognition and Scientific Medication Blue Book" presents a comprehensive view of public awareness regarding weight loss [5][29] Group 1: Public Perception and Knowledge - A high prevalence of "pseudo-science" knowledge exists, with 72.8% of surveyed women and 46.2% of men desiring to be thinner, which far exceeds the actual overweight rate of 10.58% [6] - 84.34% of respondents recognize obesity as a disease, with higher acknowledgment among those with a BMI ≥ 24 (87.66%) compared to those with a BMI < 24 (72.79%) [8] - There is a general lack of medical consultation awareness, with 84% attributing obesity to "lack of self-control" and only 11% of those trying to lose weight seeking hospital treatment [10] Group 2: Weight Perception and Medical Guidelines - Over 60% of individuals with a normal BMI perceive themselves as "slightly overweight," with 60.91% of normal-weight individuals self-identifying as "slightly overweight" [11] - The clinical pathway for obesity treatment includes screening, assessment, intervention, multidisciplinary collaboration, and long-term management, as outlined in the "Obesity Diagnosis and Treatment Guidelines (2024 Edition)" [14][26] Group 3: Medication Awareness and Misconceptions - Public sentiment towards weight loss medications is mixed, with 21.12% of normal-weight individuals using drugs to achieve weight loss, and 48.71% adjusting dosages without medical advice [19] - A common misconception is that medications can fully replace diet and exercise, with 37.14% believing this to be true, while only 27.12% understand that medications cannot substitute for lifestyle changes [22] Group 4: Long-term Weight Management - Long-term weight management relies on multidisciplinary collaboration, integrating dietary, metabolic, and behavioral interventions, with lifestyle management being crucial throughout the weight loss process [26][35] - The blue book emphasizes that effective weight management requires a personalized approach and professional team support for accurate assessment and ongoing management [30][31]

Core Insights - The obesity rate among Chinese adults has surpassed 50%, with projections indicating that by 2030, the population affected will reach 515 million people [1] - Obesity is not only a health issue but also a significant social burden, with metabolic syndromes linked to obesity causing economic losses exceeding 100 billion yuan annually [1] - The Chinese government has elevated weight management to a national public health strategy, emphasizing the need for systematic solutions rather than merely reducing weight numbers [2][6] Policy and Government Initiatives - The "Healthy China 2030" initiative includes major actions to address obesity and related health issues [1] - A "Weight Management Year" program has been launched, aiming for standardized management and scientific support for weight loss [1][2] - The government plays a crucial role in guiding policies related to weight management, which is essential for addressing chronic diseases linked to obesity [2] Market Dynamics and Drug Development - The GLP-1 drug market is expected to reach a significant scale, with projections suggesting a market size of 100 billion USD by 2030 [7] - Major players in the GLP-1 market include Novo Nordisk and Eli Lilly, which together dominate nearly 90% of the market share [3] - Local companies are also making strides, with innovative drugs like "Masitide" showing promising results in reducing visceral fat and improving metabolic syndrome indicators [4][5] Clinical Insights and Drug Efficacy - The prevalence of abdominal obesity in China is linked to various metabolic diseases, necessitating targeted solutions [3] - GLP-1 drugs have shown significant efficacy in weight loss and improving related health conditions, with some products achieving over 170% year-on-year revenue growth [3][4] - The market for weight loss drugs is diversifying, with both oral and injectable options available, each with distinct mechanisms and benefits [5] Competitive Landscape - The competition in the GLP-1 market is intensifying, with several companies, including domestic firms, preparing to enter the market as patents expire [10] - Companies are exploring new therapeutic areas for GLP-1 drugs, expanding beyond traditional uses for diabetes and obesity to include cardiovascular diseases and other conditions [9] - The development of biosimilars and new formulations is gaining momentum, with recent approvals indicating a robust pipeline in the domestic market [9][10]